INNOVIVA, INC. Interest on Convertible Debt, Net of Tax
INNOVIVA, INC. (INVA) reported Interest on Convertible Debt, Net of Tax of $4.74 million for the 12-month period ending 2021-12-31, per its 10-K/A filed 2022-03-17.
Discontinued › Notes
us-gaap:InterestOnConvertibleDebtNetOfTax · last filed 2022-03-17
- INNOVIVA, INC. interest on convertible debt, net of tax for the quarter ending 2021-12-31 was $1.18M, a 0.08% increase year-over-year.
- INNOVIVA, INC. interest on convertible debt, net of tax for the quarter ending 2021-09-30 was $1.19M, a 1.28% increase year-over-year.
- INNOVIVA, INC. interest on convertible debt, net of tax for the quarter ending 2021-06-30 was $1.16M, a 1.77% decline year-over-year.
- INNOVIVA, INC. interest on convertible debt, net of tax for the quarter ending 2021-03-31 was $1.20M, a 2.03% increase year-over-year.
- INNOVIVA, INC. interest on convertible debt, net of tax for fiscal 2021 was $4.74M, a 0.40% increase from fiscal 2020.
- INNOVIVA, INC. interest on convertible debt, net of tax for fiscal 2020 was $4.72M, a 1.48% increase from fiscal 2019.
- INNOVIVA, INC. interest on convertible debt, net of tax for fiscal 2019 was $4.65M, a 17.89% decline from fiscal 2018.
- INNOVIVA, INC. interest on convertible debt, net of tax for fiscal 2018 was $5.66M, a 0.25% increase from fiscal 2017.
| Period end | Interest on Convertible Debt, Net of Tax 3 month | Interest on Convertible Debt, Net of Tax 6 month | Interest on Convertible Debt, Net of Tax 9 month | Interest on Convertible Debt, Net of Tax 12 month |
|---|---|---|---|---|
| 2021-12-31 | $1.18M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $2.37M derived: sum of 2 quarters · filed 2022-03-17 | $3.53M derived: sum of 3 quarters · filed 2022-03-17 | $4.74M 10-K/A · filed 2022-03-17 |
| 2021-09-30 | $1.19M 10-Q · filed 2021-10-27 | $2.35M derived: sum of 2 quarters · filed 2021-10-27 | $3.55M 10-Q · filed 2021-10-27 | $4.74M derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | $1.16M 10-Q · filed 2021-07-29 | $2.37M 10-Q · filed 2021-07-29 | $3.55M derived: sum of 3 quarters · filed 2022-03-17 | $4.72M derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-03-31 | $1.20M 10-Q · filed 2021-04-28 | $2.39M derived: sum of 2 quarters · filed 2022-03-17 | $3.56M derived: sum of 3 quarters · filed 2022-03-17 | $4.74M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-12-31 | $1.18M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $2.35M derived: sum of 2 quarters · filed 2022-03-17 | $3.54M derived: sum of 3 quarters · filed 2022-03-17 | $4.72M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $1.17M 10-Q · filed 2021-10-27 | $2.35M derived: sum of 2 quarters · filed 2021-10-27 | $3.54M 10-Q · filed 2021-10-27 | $4.70M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $1.18M 10-Q · filed 2021-07-29 | $2.36M 10-Q · filed 2021-07-29 | $3.53M derived: sum of 3 quarters · filed 2022-03-17 | $4.69M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $1.18M 10-Q · filed 2021-04-28 | $2.35M derived: sum of 2 quarters · filed 2022-03-17 | $3.50M derived: sum of 3 quarters · filed 2022-03-17 | $4.66M derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $1.17M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $2.32M derived: sum of 2 quarters · filed 2022-03-17 | $3.48M derived: sum of 3 quarters · filed 2022-03-17 | $4.65M 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $1.16M 10-Q · filed 2020-10-28 | $2.31M derived: sum of 2 quarters · filed 2020-10-28 | $3.48M 10-Q · filed 2020-10-28 | $5.15M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.16M 10-Q · filed 2020-07-29 | $2.33M 10-Q · filed 2020-07-29 | $3.99M derived: sum of 3 quarters · filed 2021-02-25 | $5.41M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.42M 10-Q · filed 2020-04-29 | $2.83M derived: sum of 2 quarters · filed 2021-02-25 | $4.25M derived: sum of 3 quarters · filed 2021-02-25 | $5.66M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.83M derived: sum of 2 quarters · filed 2021-02-25 | $4.25M derived: sum of 3 quarters · filed 2021-02-25 | $5.66M 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.41M 10-Q · filed 2019-10-30 | $2.83M derived: sum of 2 quarters · filed 2019-10-30 | $4.24M 10-Q · filed 2019-10-30 | $5.66M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $1.42M 10-Q · filed 2019-07-24 | $2.83M 10-Q · filed 2019-07-24 | $4.25M derived: sum of 3 quarters · filed 2020-02-19 | $5.66M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $1.41M 10-Q · filed 2019-05-01 | $2.83M derived: sum of 2 quarters · filed 2020-02-19 | $4.24M derived: sum of 3 quarters · filed 2020-02-19 | $5.65M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $2.83M derived: sum of 2 quarters · filed 2020-02-19 | $4.24M derived: sum of 3 quarters · filed 2020-02-19 | $5.65M 10-K · filed 2020-02-19 |
| 2017-09-30 | $1.41M 10-Q · filed 2018-10-31 | $2.82M derived: sum of 2 quarters · filed 2018-10-31 | $4.23M 10-Q · filed 2018-10-31 | $10.02M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-06-30 | $1.41M 10-Q · filed 2018-07-26 | $2.82M 10-Q · filed 2018-07-26 | $8.61M derived: sum of 3 quarters · filed 2019-02-19 | $10.04M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-03-31 | $1.41M 10-Q · filed 2018-05-04 | $7.20M derived: sum of 2 quarters · filed 2019-02-19 | $8.63M derived: sum of 3 quarters · filed 2019-02-19 | $10.08M derived: sum of 4 quarters · filed 2019-02-19 |
| 2016-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $7.22M derived: sum of 2 quarters · filed 2019-02-19 | $8.68M derived: sum of 3 quarters · filed 2019-02-19 | $5.79M 10-K · filed 2019-02-19 |
| 2016-09-30 | $1.43M 10-Q · filed 2017-11-03 | $2.89M derived: sum of 2 quarters · filed 2017-11-03 | $0.00 10-Q · filed 2017-11-03 | $2.89M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | $1.46M 10-Q · filed 2017-08-08 | $0.00 10-Q · filed 2017-08-08 | $1.46M derived: sum of 3 quarters · filed 2018-02-23 | $1.46M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-05 | $0.00 derived: sum of 2 quarters · filed 2018-02-23 | $0.00 derived: sum of 3 quarters · filed 2018-02-23 | $0.00 derived: sum of 4 quarters · filed 2018-02-23 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $0.00 derived: sum of 2 quarters · filed 2018-02-23 | $0.00 derived: sum of 3 quarters · filed 2018-02-23 | $0.00 10-K · filed 2018-02-23 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $0.00 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | ||
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 | |||
| 2012-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $3.00M derived: sum of 2 quarters · filed 2013-08-01 | $4.50M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $3.00M 10-Q · filed 2013-08-01 | ||
| 2012-03-31 | $1.50M 10-Q · filed 2013-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |